Phase 2 randomized, open-label, controlled, parallel-arm study of Ampligen locally advanced pancreatic cancer
Latest Information Update: 28 Nov 2023
At a glance
- Drugs Rintatolimod (Primary)
- Indications Carcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Sponsors AIM ImmunoTech
Most Recent Events
- 15 Nov 2023 According to an AIM ImmunoTech media release, the company expects to open European site in Q4 2023.
- 15 Aug 2023 According to an AIM ImmunoTech media release, the company expects to enroll and dose first patient in this study in Q3 2023.
- 12 Apr 2022 According to an AIM ImmunoTech media release, the company engaged Amarex Clinical Research LLC, CRO for conducting this study. The company plans to initiate this study in Q3 2022.